The present invention relates to the contacting of one or more surfaces of an implantable medical device with one or more diketopiperazines (DKPs).

Disclosed is absorbable bone wax and a preparation method thereof. The preparation method comprises the steps of: 1) mixing polyoxypropylene polyoxyethylene block copolymer (PEG-PPG-PEG) and polyoxypropylene polyoxyethylene random copolymer (PEG-PPG), and stirring evenly under heating to obtain a liquid mixture; 2) under mechanical stirring and heating condition, adding hemostatic starch microspheres to the liquid mixture obtained in step 1) to obtain a uniformly-mixed liquid; and 3) adding a bone repair material to the uniformly-mixed liquid obtained in step 2), and mixing uniformly to obtain a mixed solution, then pouring the mixed solution into a mold or sub-packaged bottle, and leaving at room temperature for solidifying and shaping to give the absorbable bone wax. The absorbable bone wax of the present invention can achieve the effect of rapid hemostasis, changing the relatively single hemostasis method with traditional bone wax which only depends on physical sealing.

As described below, the present invention features compositions and methods for inhibiting inflammation in connection with an acellular template (e.g., an electrospun template). In one embodiment, the template is impregnated with an agent (e.g., N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide (Cl-amidine)) that inhibits a peptidylarginine deaminase (e.g., PAD4).

The present disclosure is directed to intracameral implants for treating and/or preventing corneal disorders, diseases, and/or conditions, such as corneal endothelial dystrophies. The intracameral implants can be configured to provide a sustained release of a therapeutic agent, such as a Rho kinase inhibitor, for a prolonged period of time. The intracameral implants can include a non-bioresorbable anchor or a bioresorbable matrix.

Angioplasty balloons coated with at least one limus drug, which may be in crystalline form, optionally with at least one excipient, and methods for manufacturing such coated angioplasty balloons.

A composition comprising a wound-closure material physically or chemically associated with an agent that reduces scarring and improves the integrity of skin and underlying tissue in a mammalian subject. Methods for reducing or eliminating scarring or improving mammalian skin integrity comprise closing a wound with a composition, such as a suture material associated with a PHD inhibitor molecule, e.g., 1,4-DPCA.

Provided herein are compounds that can exhibit activity as biofilm modulating agents (e.g., activity as biofilm inhibitors and/or activity as biofilm dispersal agents). The compounds can exhibit potent activity against Gram positive biofilms. The compounds can also exhibit activity against Gram negative biofilms. In some cases, the compounds can exhibit both biofilm modulation properties and antimicrobial activity. Compositions comprising these compounds, as well as methods of using thereof, are also described. For example, the compounds described herein can be used in human and animal health (e.g., for the treatment of infection), agriculture, marine coatings, and other coating applications related to prevention of biofilm (e.g., dental, medical, etc.).

Coatings comprising anti-microbial active particles are described, with methods of preparation and uses thereof.

Coatings comprising anti-microbial active particles are described, with methods of preparation and uses thereof.

A medical device comprising a surface, wherein a sulfanilamide is associated with the surface, and methods for making the same.